Idiopathic pneumonia syndrome after high dose chemotherapy for relapsed Hodgkin's disease

British Journal of Cancer

Volumn 75, Issue 7, 1997, Pages 1044-1048

  Rubio, C ^a   Hill, M E ^a   Milan, S ^a   O'Brien, M E R ^a   Cunningham, D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Autologous bone marrow transplantation; High dose chemotherapy; Hodgkin's disease; Idiopathic pneumonia syndrome; Peripheral stem cell transplantation

Indexed keywords

BLEOMYCIN; CARMUSTINE; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; DATA BASE; DISEASE SEVERITY; FEMALE; HODGKIN DISEASE; HUMAN; IDIOPATHIC DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MANTLE FIELD RADIOTHERAPY; MULTIVARIATE ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; STEM CELL TRANSPLANTATION;

EID: 0031002955     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.178     Document Type: Article

References (21)

1. Ahmed T (1990) Autologous marrow transplantation for Hodgkin's disease: current techniques and prospects. Cancer Invest 8: 99-106
2. Aronin PA, Mahaley MS Jr, Rudnick SA, Dudka L, Donohue JF, Selker RG and Moore P (1980) Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: assessment of risk factors. N Engl J Med 303: 183-188
3. Arrick BA and Nathan CF (1984) Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44: 4224-4232
4. Bierman P, Bagin K, Jagannath S, Vosc J, Spitzer G, Kessinger A, Dicke K and Armitage J (1993) High dose chemotherapy followed by autologous hemalopoetic rescue in Hodgkin's disease: long term follow up in 128 patients. Ann Oncol 4: 767-773
5. Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L and Peavy HH (1993) Idiopathic pneumonia syndrome after hone marrow transplantation. Am Rev Resp Dis 147: 1601-1606
6. Collis CH (1991) Chemotherapy-related morbidity to the lungs. In Complications of Cancer Management, Plowman PN, McElwain TJ and Meadows AT (eds). pp. 250-271. Butterworth Heinemann: Oxford
7. Durant JR, Norgard MJ, Murad TM, Bartolucci AA and Langford KH (1979). Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 90: 191-194
8. Goldstone AH and Mcmillan AK (1993) The place of high dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol 4: (suppl. 1): 21-27
9. Jones RJ, Plantadosi S, Mann RB, Ambinder RF Scifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD, Vogelsang GB, Wagner JH, Wiley JM, Wingard JR, Yeager AM, Saral R and Santos GW (1990) High dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8: 527-537
10. Kreisman H and Wolkove N (1992) Pulmonary toxicity of antineoplastic therapy. Semin Oncol 19: 508-502
11. Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR and Dicke KA (1981) Early pulmonary toxicity after administration of high dose BCNU. Cancer Treat Rep 65: 39-44
12. Lund MB, Kongerud J, Boe J, Nome, Abrahamsen AF, Ihlen H and Forfang K (1996) Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol 7: 257-264
13. Millard FC, Nakielny RA, Makris M and Winfield DA (1991) The chest radiograph appearances seen following high dose chemotherapy and autologous bone marrow transplantation for resistant malignan lymphoma. Br J Radio 64: 103-106
14. Miller CB, Piantadosi S, Vogelsang DC, Marcellus DC, Grochow L, Kennedy JM and Jones RJ (1996) Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 14: 1327-1332
15. National Cancer Institute (1988) Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment. National Cancer Institute: Bethesda, MD
16. O'Brien MER, Milan S, Cunningham D, Jones AL, Nicolson M, Selby P, Hickish T, Hill M, Gore MH and Viner C (1996) High dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease - a pragmatic approach. Br J Cancer 73: 1272-1277
17. Pecego R, Hill R, Appelbauin FR, Amos D, Buckner CD, Fefer A and Thomas ED (1986) Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 42: 515-517
18. Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE and Kramer BS (1983) Intensive 1,3-bis-(2-chloroethyl)-1 nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 52: 1792-1802
19. Reece DH, Barnett MJ, Connors JH, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, Lemaistre CF, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff and Phillips GL (1991) Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9: 1871-1879
20. Weaver C, Appelbaum H, Peterson F, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Dony K, Hansen J, Petersdorf E, Rowley S, Storb R, Sullivan K, Witherspoon R, Weiden P and Buckner C (1993) High dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11: 1329-1335
21. Wheeler C, Antin J, Churchill W, Come S, Smith B, Buhley G, Rosenlhal D, Rappaport J, Ault K, Schnipper L and Eder J (1990) Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose finding study. J Clin Oncol 8: 648-656